论文部分内容阅读
目的:考察不同载药量的灯盏花素巴布剂经皮促渗作用。方法:采用透皮扩散仪考察不同载药量灯盏花素巴布剂离体透皮促渗作用;采用微渗析技术考察其在体经皮促渗作用。结果:载药量为1.5%、1.0%、0.5%的灯盏花素巴布剂的体外累计透过量分别为289.15、260.435、158.625μg/cm2;载药量为1.5%、1.0%、0.5%的灯盏花素巴布剂的在体累计透过量分别为8.32、6.53、6.38μg/cm2。结论:灯盏花素巴布剂随着载药量的提高,经皮促渗作用增强,是具有前景的经皮给药载体。
Objective: To investigate the percutaneous effect of breviscapine with different drug loadings. Methods: The percutaneous dermal diffusion apparatus was used to investigate the percutaneous dermal penetration of Breviscapine in different doses. The micro-dialysis technique was used to investigate the percutaneous dermal penetration. Results: The cumulative transdermal doses of Breviscapine Patch with drug loadings of 1.5%, 1.0% and 0.5% were 289.15, 260.435 and 158.625μg / cm2, respectively; the drug loadings were 1.5%, 1.0%, 0.5% Breviscapine cataplasm in vivo cumulative transmission were 8.32,6.53,6.38μg / cm2. Conclusion: Breviscapine poultice is a promising transdermal delivery carrier with the increase of drug loading and the enhancement of percutaneous permeability.